We are very pleased to announce that we had added another Japanese client to Aagami family. Client is a Japan based company specializing in Contr...
Published : 01 Oct 2024
Read MoreAagami is pleased to announce that during the period of July to September, multiple clients have awarded contract extensions to Aagami.US based Geneti...
Published : 16 Sep 2024
Read MoreAagami CEO Dinesh Jain is visiting Japan and Korea and will be meeting 30+ decision makers (mostly in Japanese and Korean companies). This includ...
Published : 04 Sep 2024
Read MoreWe are thrilled to share that Venture Capital Arm of a large global pharma group has invested in two Aagami Client opportunities. Both clients ar...
Published : 06 Aug 2024
Read MoreWe are excited to announce that Aagami is attending the International Life Sciences Partnering Conference – BIO-Europe® 2024 ( Novem...
Published : 12 Jul 2024
Read MoreAagami has received a new assignment as a result of one of the recently concluded BIO 2024 partnering event. The assignment has come from a past ...
Published : 23 Jun 2024
Read MoreAagami successfully completed BIO International Convention 2024 (June 3-6) in San Diego with 40+ one-on-one meetings with decision makers in Biotech, ...
Published : 10 Jun 2024
Read MoreNanoViricides, Inc. (NYSE Amer.: NNVC) (the "Company"), a clinical-stage global leader in broad-spectrum antiviral nanomedicines, has engaged Aag...
Published : 21 May 2024
Read MoreAagami, Inc. are pleased to announce that another US client has awarded a contract extension to support them in JV/Acquisition initiatives. We thank t...
Published : 15 May 2024
Read MoreAagami has won a New Client from Alabama, USA. The client is a clinical-stage biopharmaceutical company advancing the next generation of new anti-infl...
Published : 12 Mar 2024
Read More